{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:15:43Z","timestamp":1788311743626,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Luzern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Optimal follow-up strategies following trimodal treatment for muscle invasive bladder cancer play a crucial role in detecting and managing relapse and side-effects. This article provides a comprehensive summary of the patterns and risk factors of relapse, functional outcomes, and follow-up protocols.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature search on PubMed and review of current guidelines and institutional follow-up protocols after trimodal therapy were conducted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of 200 identified publications, 43 studies (28 retrospective, 15 prospective) were selected, encompassing 7447 patients (study sizes from 24 to 728 patients). Recurrence rates in the urinary bladder varied between 14\u201352%; 3\u201316% were muscle-invasive while 11\u201336% were non-muscle invasive. Nodal recurrence occurred at 13\u201316% and\u00a0distant metastases at 15\u201335%. After 5 and 10\u00a0years of follow-up, around 60\u201385% and 45\u201375% of patients could preserve their bladder, respectively. Various prognostic risk factors associated with relapse and inferior survival were proposed, including higher disease stage (&gt;\u2009c\/pT2), presence of extensive\/multifocal carcinoma in situ (CIS), hydronephrosis, multifocality, histological subtypes, incomplete transurethral resection of bladder tumor (TURBT) and\u00a0incomplete response to radio-chemotherapy. The analyzed follow-up guidelines varied slightly in terms of the number, timing, and types of investigations, but overall, the recommendations were similar.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Randomized prospective studies should focus on evaluating the impact of specific follow-up protocols on oncological and functional outcomes following trimodal treatment for muscle-invasive bladder cancer. It is crucial to evaluate personalized adaption of follow-up protocols based on established risk factors, as there is potential for improved patient outcomes and resource allocation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-05196-7","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T14:21:10Z","timestamp":1726755670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review"],"prefix":"10.1007","volume":"42","author":[{"given":"Ernest","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Aeppli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Bieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berardino","family":"de Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Engeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4493-1301","authenticated-orcid":false,"given":"Thomas R. W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucca","family":"Ilaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Laouiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostino","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"M\u00fcntener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Niederberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Papachristofilou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Prause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Salati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"S\u00e8be","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e4to","family":"Strebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud J.","family":"Templeton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian S.","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Zihler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zwahlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4073-5488","authenticated-orcid":false,"given":"Christian","family":"Fankhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"5196_CR1","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD (2020) Bladder cancer: a review. JAMA 324:1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598","journal-title":"JAMA"},{"key":"5196_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"JWF Catto","year":"2021","unstructured":"Catto JWF, Downing A, Mason S, Wright P, Absolom K, Bottomley S et al (2021) Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur Urol 79:621\u2013632. https:\/\/doi.org\/10.1016\/j.eururo.2021.01.032","journal-title":"Eur Urol"},{"key":"5196_CR3","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","volume":"96","author":"KS Mak","year":"2016","unstructured":"Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS et al (2016) Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 96:1028\u20131036. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.08.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5196_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366:1477\u20131488. https:\/\/doi.org\/10.1056\/NEJMoa1106106","journal-title":"N Engl J Med"},{"key":"5196_CR5","doi-asserted-by":"publisher","unstructured":"Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP et al. (2022) Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol. 40: 272. https:\/\/doi.org\/10.1016\/j.urolonc.2021.12.015","DOI":"10.1016\/j.urolonc.2021.12.015"},{"key":"5196_CR6","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/jco.2016.69.2327","volume":"35","author":"GS Kulkarni","year":"2017","unstructured":"Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P et al (2017) Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol 35:2299\u20132305. https:\/\/doi.org\/10.1200\/jco.2016.69.2327","journal-title":"J Clin Oncol"},{"key":"5196_CR7","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1200\/jco.2014.57.5548","volume":"32","author":"RH Mak","year":"2014","unstructured":"Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32:3801\u20133809. https:\/\/doi.org\/10.1200\/jco.2014.57.5548","journal-title":"J Clin Oncol"},{"key":"5196_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","volume":"71","author":"NJ Giacalone","year":"2017","unstructured":"Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM et al (2017) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the massachusetts general hospital experience. Eur Urol 71:952\u2013960. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.020","journal-title":"Eur Urol"},{"key":"5196_CR9","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jjco\/hyac095","volume":"52","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Matsumoto H, Misumi T, Ito H, Hirata H, Nagao K et al (2022) The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study. Jpn J Clin Oncol 52:1201\u20131207. https:\/\/doi.org\/10.1093\/jjco\/hyac095","journal-title":"Jpn J Clin Oncol"},{"key":"5196_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/s1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G et al (2023) Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 24:669\u2013681. https:\/\/doi.org\/10.1016\/s1470-2045(23)00170-5","journal-title":"Lancet Oncol"},{"key":"5196_CR11","doi-asserted-by":"publisher","first-page":"e191629","DOI":"10.1001\/jamasurg.2019.1629","volume":"154","author":"SB Williams","year":"2019","unstructured":"Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS et al (2019) Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer. JAMA Surg 154:e191629. https:\/\/doi.org\/10.1001\/jamasurg.2019.1629","journal-title":"JAMA Surg"},{"key":"5196_CR12","doi-asserted-by":"publisher","unstructured":"Golla V, Shan Y, Farran EJ, Stewart CA, Vu K, Yu A, et al. (2022) Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urol Oncol. 40: 273.e1-.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2022.01.007","DOI":"10.1016\/j.urolonc.2022.01.007"},{"key":"5196_CR13","doi-asserted-by":"publisher","unstructured":"Suskovic N, Raldow AC, Royce TJ, Smith A (2020) Cost-effectiveness of radical cystectomy versus trimodality therapy for muscle invasive bladder cancer. J Clin Oncol. 38: 575. https:\/\/doi.org\/10.1200\/JCO.2020.38.6_suppl.575","DOI":"10.1200\/JCO.2020.38.6_suppl.575"},{"key":"5196_CR14","doi-asserted-by":"publisher","unstructured":"Kool R, Yanev I, Hijal T, Vanhuyse M, Cury FL, Souhami L, et al. (2022) Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Canadian cost-effectiveness analysis. Canadian Urological Association journal = Journal de l'Association des urologues du Canada; 16:189\u201398. https:\/\/doi.org\/10.5489\/cuaj.7430","DOI":"10.5489\/cuaj.7430"},{"key":"5196_CR15","doi-asserted-by":"publisher","unstructured":"Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK et al. (2020) Bladder cancer, version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 18: 329-354. https:\/\/doi.org\/10.6004\/jnccn.2020.0011","DOI":"10.6004\/jnccn.2020.0011"},{"key":"5196_CR16","volume-title":"Oncological surveillance after radical cystectomy, a narrative review of the enhanced recovery after surgery (ERAS) cystectomy committee","author":"E Kaufmann","year":"2023","unstructured":"Kaufmann E, Black PC, Catto JW, Djaladat H, Ghodoussipour S, Hamilton-Reeves JM et al (2023) Oncological surveillance after radical cystectomy, a narrative review of the enhanced recovery after surgery (ERAS) cystectomy committee. In Press, JU Open Plus"},{"key":"5196_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","volume":"198","author":"SS Chang","year":"2017","unstructured":"Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP et al (2017) Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO Guideline. J Urol 198:552\u2013559. https:\/\/doi.org\/10.1016\/j.juro.2017.04.086","journal-title":"J Urol"},{"key":"5196_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G et al (2021) European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines. Eur Urol 79:82\u2013104. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"key":"5196_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y et al (2022) Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","journal-title":"Ann Oncol"},{"key":"5196_CR20","unstructured":"(2020) S3-Leitlinie Fr\u00fcherkennung, diagnose, therapie und nachsorge des harnblasenkarzinoms. AWMF Online das portal der wissenschaftlichen Medizin; Version 2.0 M\u00e4rz 2020: 330-1"},{"key":"5196_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.humpath.2022.04.013","volume":"126","author":"G Evaristo","year":"2022","unstructured":"Evaristo G, Khadang B, Kool R, Marcq G, Farag MS, Kassouf W et al (2022) Morphologic alterations post trimodal therapy in muscle-invasive urothelial carcinoma: understanding the impact of post-treatment changes on the pathological interpretation and their potential clinical correlates. Hum Pathol 126:2\u20138. https:\/\/doi.org\/10.1016\/j.humpath.2022.04.013","journal-title":"Hum Pathol"},{"key":"5196_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/s0302-2838(03)00059-9","volume":"43","author":"BW van Rhijn","year":"2003","unstructured":"van Rhijn BW, Smit M, van Geenen D, Wijnmaalen A, Kirkels WJ, van der Kwast TH et al (2003) Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy. Eur Urol 43:369\u2013373. https:\/\/doi.org\/10.1016\/s0302-2838(03)00059-9","journal-title":"Eur Urol"},{"key":"5196_CR23","doi-asserted-by":"publisher","unstructured":"McLoughlin LC, O\u2019Halloran S, Tjong M, Ajib K, Lajkosz K, Ruff H et al. (2022) The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. Urol Oncol. 40: 346.e9-.e16. https:\/\/doi.org\/10.1016\/j.urolonc.2022.02.021","DOI":"10.1016\/j.urolonc.2022.02.021"},{"key":"5196_CR24","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1002\/cam4.5840","volume":"12","author":"R Krishnatry","year":"2023","unstructured":"Krishnatry R, Maitre P, Kumar A, Telkhade T, Bakshi G, Prakash G et al (2023) Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer. Cancer Med 12:11305\u201311314. https:\/\/doi.org\/10.1002\/cam4.5840","journal-title":"Cancer Med"},{"key":"5196_CR25","doi-asserted-by":"publisher","unstructured":"Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L et al. (2016) Recommendations for the improvement of bladder cancer quality of care in Canada: a consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canad Urol Assoc J. 10: E46-80. https:\/\/doi.org\/10.5489\/cuaj.3583","DOI":"10.5489\/cuaj.3583"},{"key":"5196_CR26","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/jco.2002.11.027","volume":"20","author":"C R\u00f6del","year":"2002","unstructured":"R\u00f6del C, Grabenbauer GG, K\u00fchn R, Papadopoulos T, Dunst J, Meyer M et al (2002) Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20:3061\u20133071. https:\/\/doi.org\/10.1200\/jco.2002.11.027","journal-title":"J Clin Oncol"},{"key":"5196_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","volume":"61","author":"JA Efstathiou","year":"2012","unstructured":"Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A et al (2012) Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 61:705\u2013711. https:\/\/doi.org\/10.1016\/j.eururo.2011.11.010","journal-title":"Eur Urol"},{"key":"5196_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","volume":"199","author":"A Sanchez","year":"2018","unstructured":"Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodr\u00edguez D et al (2018) Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer. J Urol 199:407\u2013415. https:\/\/doi.org\/10.1016\/j.juro.2017.08.106","journal-title":"J Urol"},{"key":"5196_CR29","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1200\/jco.2008.19.5776","volume":"27","author":"JA Efstathiou","year":"2009","unstructured":"Efstathiou JA, Bae K, Shipley WU, Kaufman DS, Hagan MP, Heney NM et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89\u201303, 95\u201306, 97\u201306, 99\u201306. J Clin Oncol 27:4055\u20134061. https:\/\/doi.org\/10.1200\/jco.2008.19.5776","journal-title":"J Clin Oncol"},{"key":"5196_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der K, Christensen E, Nordentoft I, Knudsen M, Taber A, H\u00f8yer S et al (2018) Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur Urol 73:535\u2013540. https:\/\/doi.org\/10.1016\/j.eururo.2017.09.011","journal-title":"Eur Urol"},{"key":"5196_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der K, Nordentoft I, Christensen E, H\u00f8yer S, Reinert T, Vang S et al (2016) Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70:75\u201382. https:\/\/doi.org\/10.1016\/j.eururo.2016.01.007","journal-title":"Eur Urol"},{"key":"5196_CR32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC et al (2021) ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595:432\u2013437. https:\/\/doi.org\/10.1038\/s41586-021-03642-9","journal-title":"Nature"},{"key":"5196_CR33","doi-asserted-by":"publisher","unstructured":"Carrasco R, Ingelmo-Torres M, G\u00f3mez A, Trullas R, Rold\u00e1n FL, Ajami T, et al. (2022) Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer. Int J Mol Sci. 23: 11732. https:\/\/doi.org\/10.3390\/ijms231911732","DOI":"10.3390\/ijms231911732"},{"key":"5196_CR34","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/j.annonc.2021.08.112","volume":"32","author":"TB Powles","year":"2021","unstructured":"Powles TB, Gschwend JE, Bracarda S, Castellano D, Gross-Goupil M, Bjerggaard Jensen J et al (2021) 716TiP IMvigor011: a global, double-blind, randomised phase III study of atezolizumab (atezo; anti\u2013PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy. Ann Oncol 32:S721. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.112","journal-title":"Ann Oncol"},{"key":"5196_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13148-021-01029-1","volume":"13","author":"P Piatti","year":"2021","unstructured":"Piatti P, Chew YC, Suwoto M, Yamada T, Jara B, Jia XY et al (2021) Clinical evaluation of bladder CARE, a new epigenetic test for bladder cancer detection in urine samples. Clin Epigenetics 13:84. https:\/\/doi.org\/10.1186\/s13148-021-01029-1","journal-title":"Clin Epigenetics"},{"key":"5196_CR36","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.1158\/1078-0432.Ccr-23-0570","volume":"29","author":"K Salari","year":"2023","unstructured":"Salari K, Sundi D, Lee JJ, Wu S, Wu CL, DiFiore G et al (2023) Development and multicenter case-control validation of urinary comprehensive genomic profiling for urothelial carcinoma diagnosis, surveillance, and risk-prediction. Clin Cancer Res 29:3668\u20133680. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-0570","journal-title":"Clin Cancer Res"},{"key":"5196_CR37","doi-asserted-by":"publisher","unstructured":"Lotan Y SK, Feldman A, Sundi D, Lee J, DiFiore G, Poustchi H, Khoshnia M, Roshandel G, Etemadi A, Goudarzi M, Lentz PS, Phillips KG, Bicocca VT, Koppie TM, Gray JW, Levin T, Reza M, Sheikh M, Calvez-Kelm FL (2023) MP22-19 Urinary comprehensive genomic profiling predicts urothelial cancer up to 12\u00a0years ahead of clinical diagnosis An expanded analysis of the Golestan Cohort study. American Urological Society abstract. 209(suppl 4): e304. https:\/\/doi.org\/10.1097\/JU.0000000000003247.19","DOI":"10.1097\/JU.0000000000003247.19"},{"key":"5196_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ijrobp.2018.12.028","volume":"104","author":"W Meng","year":"2019","unstructured":"Meng W, Efstathiou J, Singh R, McElroy J, Volinia S, Cui R et al (2019) MicroRNA biomarkers for patients with muscle-invasive bladder cancer undergoing selective bladder-sparing trimodality treatment. Int J Radiat Oncol Biol Phys 104:197\u2013206. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.028","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5196_CR39","doi-asserted-by":"publisher","unstructured":"Swinton M, Mariam NBG, Tan JL, Murphy K, Elumalai T, Soni M, et al. (2023) Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer. J Clin Oncol.41: 4406-4415. https:\/\/doi.org\/10.1200\/jco.23.00725","DOI":"10.1200\/jco.23.00725"},{"key":"5196_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.urolonc.2008.07.005","volume":"28","author":"MA Sabaa","year":"2010","unstructured":"Sabaa MA, El-Gamal OM, Abo-Elenen M, Khanam A (2010) Combined modality treatment with bladder preservation for muscle invasive bladder cancer. Urol Oncol 28:14\u201320. https:\/\/doi.org\/10.1016\/j.urolonc.2008.07.005","journal-title":"Urol Oncol"},{"key":"5196_CR41","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","volume":"72","author":"RE Krasnow","year":"2017","unstructured":"Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S et al (2017) Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol 72:54\u201360. https:\/\/doi.org\/10.1016\/j.eururo.2016.12.002","journal-title":"Eur Urol"},{"key":"5196_CR42","doi-asserted-by":"publisher","unstructured":"Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, et al. (2022) Differences in cancer-specific mortality after trimodal therapy for T2N0M0 bladder cancer according to histological subtype. Cancers. 14: 5766. https:\/\/doi.org\/10.3390\/cancers14235766","DOI":"10.3390\/cancers14235766"},{"key":"5196_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.urology.2018.07.058","volume":"124","author":"D B\u00fcchser","year":"2019","unstructured":"B\u00fcchser D, Zapatero A, Rogado J, Talaya M, Mart\u00edn de Vidales C, Arellano R et al (2019) Long-term outcomes and patterns of failure following trimodality treatment with bladder preservation for invasive bladder cancer. Urology 124:183\u2013190. https:\/\/doi.org\/10.1016\/j.urology.2018.07.058","journal-title":"Urology"},{"key":"5196_CR44","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jgo.2022.05.014","volume":"13","author":"A Alati","year":"2022","unstructured":"Alati A, Fabiano E, Geiss R, Mareau A, Charles-Nelson A, Bibault JE et al (2022) Bladder preservation in older adults with muscle-invasive bladder cancer: a retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule. J Geriatr Oncol 13:978\u2013986. https:\/\/doi.org\/10.1016\/j.jgo.2022.05.014","journal-title":"J Geriatr Oncol"},{"key":"5196_CR45","doi-asserted-by":"publisher","unstructured":"Fabiano E, Durdux C, Dufour B, Mejean A, Thiounn N, Chr\u00e9tien Y, et al. (2021) Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer. Acta Oncol (Stockholm, Sweden). 60: 794-802. https:\/\/doi.org\/10.1080\/0284186x.2021.1915498","DOI":"10.1080\/0284186x.2021.1915498"},{"key":"5196_CR46","first-page":"874","volume":"61","author":"MA Tunio","year":"2011","unstructured":"Tunio MA, Hashmi A, Qayyum A, Naimatullah N, Mohsin R, Sultan G (2011) Outcome of trimodality protocol for invasive bladder cancer patients at Karachi, Pakistan. J Pak Med Assoc 61:874\u2013879","journal-title":"J Pak Med Assoc"},{"key":"5196_CR47","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/s0090-4295(01)01219-5","volume":"58","author":"AL Zietman","year":"2001","unstructured":"Zietman AL, Grocela J, Zehr E, Kaufman DS, Young RH, Althausen AF et al (2001) Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58:380\u2013385. https:\/\/doi.org\/10.1016\/s0090-4295(01)01219-5","journal-title":"Urology"},{"key":"5196_CR48","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2019.11.001","volume":"77","author":"RA Huddart","year":"2020","unstructured":"Huddart RA, Hall E, Lewis R, Porta N, Crundwell M, Jenkins PJ et al (2020) Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy \u00b1 chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 77:260\u2013268. https:\/\/doi.org\/10.1016\/j.eururo.2019.11.001","journal-title":"Eur Urol"},{"key":"5196_CR49","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","volume":"170","author":"AL Zietman","year":"2003","unstructured":"Zietman AL, Sacco D, Skowronski U, Gomery P, Kaufman DS, Clark JA et al (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170:1772\u20131776. https:\/\/doi.org\/10.1097\/01.ju.0000093721.23249.c3","journal-title":"J Urol"},{"key":"5196_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00192-013-2151-6","volume":"25","author":"C Katepratoom","year":"2014","unstructured":"Katepratoom C, Manchana T, Amornwichet N (2014) Lower urinary tract dysfunction and quality of life in cervical cancer survivors after concurrent chemoradiation versus radical hysterectomy. Int Urogynecol J 25:91\u201396. https:\/\/doi.org\/10.1007\/s00192-013-2151-6","journal-title":"Int Urogynecol J"},{"key":"5196_CR51","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12885-023-10869-4","volume":"23","author":"J Hyun","year":"2023","unstructured":"Hyun J, Ha MS, Oh SY, Tae JH, Chi BH, Chang IH et al (2023) Urinary tract infection after radiation therapy or radical prostatectomy on the prognosis of patients with prostate cancer: a population-based study. BMC Cancer 23:395. https:\/\/doi.org\/10.1186\/s12885-023-10869-4","journal-title":"BMC Cancer"},{"key":"5196_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.radonc.2020.07.057","volume":"150","author":"CS Voskuilen","year":"2020","unstructured":"Voskuilen CS, van de Kamp MW, Schuring N, Mertens LS, Noordzij A, Pos F et al (2020) Radiation with concurrent radiosensitizing capecitabine tablets and single-dose mitomycin-C for muscle-invasive bladder cancer: a convenient alternative to 5-fluorouracil. Radiother Oncol 150:275\u2013280. https:\/\/doi.org\/10.1016\/j.radonc.2020.07.057","journal-title":"Radiother Oncol"},{"key":"5196_CR53","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bju.15739","volume":"130","author":"JA Lane","year":"2022","unstructured":"Lane JA, Donovan JL, Young GJ, Davis M, Walsh EI, Avery KNL et al (2022) Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU Int 130:370\u2013380. https:\/\/doi.org\/10.1111\/bju.15739","journal-title":"BJU Int"},{"key":"5196_CR54","first-page":"854","volume":"5","author":"S Zhang","year":"2015","unstructured":"Zhang S, Yu YH, Zhang Y, Qu W, Li J (2015) Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application. Am J Cancer Res 5:854\u2013868","journal-title":"Am J Cancer Res"},{"key":"5196_CR55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.5114\/wo.2020.100275","volume":"24","author":"M Rastogi","year":"2020","unstructured":"Rastogi M, Gandhi AK, Tiwari R, Nanda SS, Rath S, Khurana R et al (2020) Prospective evaluation of definitive chemoradiotherapy with volumetric modulated arc therapy in patients with muscle invasive carcinoma of urinary bladder. Contemp Oncol (Pozn) 24:177\u2013182. https:\/\/doi.org\/10.5114\/wo.2020.100275","journal-title":"Contemp Oncol (Pozn)"},{"key":"5196_CR56","doi-asserted-by":"publisher","unstructured":"Huddart R, Hafeez S, Omar A, Alonzi R, Birtle A, Cheung KC, et al. (2023) Acute toxicity of hypofractionated and conventionally fractionated (Chemo)radiotherapy regimens for bladder cancer: an exploratory analysis from the RAIDER Trial. Clin Oncol (Royal College of Radiologists (Great Britain)). 35: 586-97. https:\/\/doi.org\/10.1016\/j.clon.2023.05.002","DOI":"10.1016\/j.clon.2023.05.002"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05196-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:22:26Z","timestamp":1735852946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05196-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5196"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05196-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients provided written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"527"}}